# DF/HCC Kidney Cancer SPORE

> **NIH NIH P50** · BETH ISRAEL DEACONESS MEDICAL CENTER · 2021 · $2,272,484

## Abstract

Summary
This application represents a resubmission of a competing renewal application for a Specialized Program of
Research Excellence (SPORE) in Kidney Cancer from the Kidney Cancer Program of Dana-Farber/Harvard
Cancer Center (DF/HCC). The DF/HCC Kidney Cancer SPORE has been funded for two cycles since 2003.
DF/HCC is comprised of the following institutions: Beth Israel-Deaconess Medical Center (BIDMC); Dana-
Farber Cancer Institute (DFCI); Harvard Medical School; Harvard School of Public Health; Brigham and
Women’s Hospital; Massachusetts General Hospital (MGH); and Children’s Hospital of Boston. In addition to
the institutions in the DF/HCC, the Georgetown-Lombardi Cancer Center (GLCC) is collaborating institutions
in this grant. The DF/HCC Kidney Cancer SPORE has its administrative base at the BIDMC. Dr. David
McDermott, who has led the DF/HCC Kidney Cancer Program and SPORE since 2012 is joined as SPORE
Director by Dr. William Kaelin, a laboratory scientist at DFCI and has served with Dr. McDermott as Director
of the SPORE since early 2014. Dr. Kaelin is a world renowned basic and translational investigator with
longstanding interest in renal cancer and a leader within the DF/HCC community. Drs. McDermott and Kaelin
report directly to Dr. Laurie Glimcher, Director of DF/HCC and President of DFCI. The DF/HCC Kidney
Cancer SPORE has a broad and deep talent base and there is extensive institutional commitment. We take
advantage of a large patient population and cutting edge technologies that are available to us as part of
DF/HCC. We propose 3 Projects which address critical problems in kidney cancer and have translational
components. They focus on identifying effective strategies for targeting: HIF2α, the dominant oncogenic
driver of clear-cell RCC (Project 1), resistance mechanisms of standard therapies (Projects 2-3, DRP 17),
novel immune checkpoint pathways (Project 3) and rare kidney tumor types (e.g. NF2 mutated and
translocation RCC, DRP 18 and 17). The projects are supported by three Cores - an Administrative Core, a
Biostatistics and Computational Biology Core, and a Tissue Acquisition, Pathology and Clinical Data Core.
We also have a highly successful Career Development Program that selects talented physician scientists and
mentors them to independence as well as a Developmental Projects Program that generates new ideas for
the SPORE in the future. The existence of the SPORE has provided opportunities and incentives to extend
basic science and clinical research ideas into the translational realm and facilitated the entry of young, as well
as some seasoned, investigators into the kidney cancer field where they have made major contributions.

## Key facts

- **NIH application ID:** 10206018
- **Project number:** 5P50CA101942-17
- **Recipient organization:** BETH ISRAEL DEACONESS MEDICAL CENTER
- **Principal Investigator:** WILLIAM G. KAELIN
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,272,484
- **Award type:** 5
- **Project period:** 2003-09-18 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10206018

## Citation

> US National Institutes of Health, RePORTER application 10206018, DF/HCC Kidney Cancer SPORE (5P50CA101942-17). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10206018. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*